We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aduro's Cancer Arm & Strong Collaborations Boost Growth
Read MoreHide Full Article
On Sep 17, we issued an updated research report on Aduro Biotech, Inc. .
Aduro’s three distinct technology platforms, designed to harness the body's natural immune system, are being utilized to develop treatments for several cancer indications and show potential to be expanded into auto-immune and infectious diseases. The three distinct platforms are the live, attenuated, double-deleted (LADD) technology platform, TING pathway activator platform and the B-select monoclonal antibody platform.
So far this year, shares of Aduro have lost 17.4%, wider than the industry’s decrease of 5.9%.
Interesting candidates in the LADD platform include ADU-623 (phase I–glioblastoma), ADU-741 (phase I – metastatic castration resistant prostate cancer) and ADU-214 (phase I – metastatic non-small cell lung cancer). Aduro has a research and license agreement with Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , for developing ADU-214 and ADU-741.
In June, Aduro announced having initiated a phase Ib study of ADU-214 in combination with Bristol-Myers’ (BMY - Free Report) Opdivo (nivolumab) for treating advanced lung cancer. Johnson & Johnson’s affiliate Janssen — Aduro’s license partner for ADU-214 — is conducting this global analysis.
Further, Aduro has a collaboration and license agreement with Novartis (NVS - Free Report) for developing its lead STING Activator candidate ADU-S100. The same is being evaluated in a phase I program as a monotherapy on patients with cutaneously accessible metastatic solid tumors or lymphomas. Top-line data from the program is expected soon.
Aduro is also performing a phase Ib study to assess ADU-S100 in combination with Novartis’ PD-1 checkpoint inhibitor, PDR001, for treating solid tumors and lymphomas.
Aduro’s B-select monoclonal antibody platform has a number of immune modulating assets, currently in research and pre-clinical development stage. Agents from this platform, such as anti-APRIL, anti-CTLA4 and anti-PD1, exhibit promises to generate novel immunotherapy combinations. Last December, Aduro announced to have begun a phase I/II dose escalation program, analyzing its pipeline candidate, BION-1301, for treating adults with relapsed or refractory multiple myeloma.
In August, the United States Patent and Trademark Office granted a new composition of matter patent protecting the BION-1301.
Notably, Aduro’s collaboration agreements with large pharma entities like Novartis (NVS - Free Report) and Johnson & Johnson (JNJ - Free Report) validate the company’s research platforms as well as enhance its financial position, providing it with adequate funds.
It is important to know that Aduro’s portfolio remains devoid of an approved product. Thus, an inability to secure sufficient funding from its collaboration and license agreements could hinder the company’s pipeline progress.
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
Aduro's Cancer Arm & Strong Collaborations Boost Growth
On Sep 17, we issued an updated research report on Aduro Biotech, Inc. .
Aduro’s three distinct technology platforms, designed to harness the body's natural immune system, are being utilized to develop treatments for several cancer indications and show potential to be expanded into auto-immune and infectious diseases. The three distinct platforms are the live, attenuated, double-deleted (LADD) technology platform, TING pathway activator platform and the B-select monoclonal antibody platform.
So far this year, shares of Aduro have lost 17.4%, wider than the industry’s decrease of 5.9%.
Interesting candidates in the LADD platform include ADU-623 (phase I–glioblastoma), ADU-741 (phase I – metastatic castration resistant prostate cancer) and ADU-214 (phase I – metastatic non-small cell lung cancer). Aduro has a research and license agreement with Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , for developing ADU-214 and ADU-741.
In June, Aduro announced having initiated a phase Ib study of ADU-214 in combination with Bristol-Myers’ (BMY - Free Report) Opdivo (nivolumab) for treating advanced lung cancer. Johnson & Johnson’s affiliate Janssen — Aduro’s license partner for ADU-214 — is conducting this global analysis.
Further, Aduro has a collaboration and license agreement with Novartis (NVS - Free Report) for developing its lead STING Activator candidate ADU-S100. The same is being evaluated in a phase I program as a monotherapy on patients with cutaneously accessible metastatic solid tumors or lymphomas. Top-line data from the program is expected soon.
Aduro is also performing a phase Ib study to assess ADU-S100 in combination with Novartis’ PD-1 checkpoint inhibitor, PDR001, for treating solid tumors and lymphomas.
Aduro’s B-select monoclonal antibody platform has a number of immune modulating assets, currently in research and pre-clinical development stage. Agents from this platform, such as anti-APRIL, anti-CTLA4 and anti-PD1, exhibit promises to generate novel immunotherapy combinations. Last December, Aduro announced to have begun a phase I/II dose escalation program, analyzing its pipeline candidate, BION-1301, for treating adults with relapsed or refractory multiple myeloma.
In August, the United States Patent and Trademark Office granted a new composition of matter patent protecting the BION-1301.
Notably, Aduro’s collaboration agreements with large pharma entities like Novartis (NVS - Free Report) and Johnson & Johnson (JNJ - Free Report) validate the company’s research platforms as well as enhance its financial position, providing it with adequate funds.
It is important to know that Aduro’s portfolio remains devoid of an approved product. Thus, an inability to secure sufficient funding from its collaboration and license agreements could hinder the company’s pipeline progress.
Aduro Biotech, Inc. Price
Aduro Biotech, Inc. Price | Aduro Biotech, Inc. Quote
Zacks Rank
Aduro currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>